Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConM SOSIP.v7 gp140 vaccine in healthy adults
NCT03961438Phase 1Completed
- Sponsor
- University of Amsterdam
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ConM SOSIP in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Amsterdam. Primary endpoints: Adverse events and Vaccine-related serious adverse events at 18 months. Started Nov 2019; status: completed.
02
Drugs
ConM SOSIP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03961438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961438.